NLRP3 and atherosclerosis: Statin therapy can down-regulate NLRP3, cathepsin-B, and downstream mediators such as IL-1β, which play a significant role in inflammation associated with atherosclerosis and reduce NLRP3 gene expression in PBMCs of CVD patients [59].